

Kyowa Hakko Kirin Co., Ltd.**Appendix to the Fiscal 2012 Third Quarter Consolidated Financial Statements**

Third quarter results for Fiscal 2012
(January 1, 2012 - September 30, 2012)

Index	Page
I. Consolidated Financial results	
1. Income	1
2. Results by segment	1
3. Non-operating income/expenses	2
4. Extraordinary income/losses	2
5. R&D expenses	3
6. Capital expenditure (tangible fixed assets)	3
7. Depreciation expenses	3
8. Exchange rates	3
II. Consolidated Subsidiaries and Affiliates	4
III. Non-Consolidated Net sales by division	
1. Kyowa Hakko Kirin	5
2. ProStrakan	6
3. Kyowa Hakko Bio	6
R&D Pipeline	7

This document is a supplement to the Kessan Tanshin (financial report) for the third quarter period of the fiscal year ending December 31, 2012 as filed with the Tokyo Stock Exchange on 26 October 2012. This document contains forecasts and forward-looking statements based on information and assumptions which management believes to be reasonable in the light of information currently available. However, actual financial results may differ materially from the forecasts presented here for a variety of reasons.

I. Consolidated Financial Results

1. Trends in income

Millions of yen, rounded down

	FY2011 results			FY 2012 results				FY 2012 forecasts
	January 1 to June 30	January 1 to September 30 (A)	January 1 to December 31	January 1 to June 30	January 1 to September 30 (B)	Change on January to September 2011		January to December
						Amount (B-A)	%	
Net sales	186,367	262,358	343,722	166,290	244,691	(17,667)	93%	333,000
Gross Profit	100,234	147,334	197,555	104,321	154,386	7,051	105%	--
Selling, general and administrative expenses	70,297	108,830	150,940	78,736	117,043	8,212	108%	--
Operating income (before amortization of goodwill)	34,576	45,456	55,881	30,212	44,283	(1,173)	97%	61,255
Operating income	29,936	38,503	46,614	25,585	37,343	(1,160)	97%	52,000
Non-operating income	1,316	1,878	2,233	1,419	1,933	55		--
Non-operating expenses	1,040	1,858	2,093	3,909	6,694	4,835		--
Ordinary income	30,212	38,523	46,754	23,094	32,581	(5,914)	85%	46,500
Extraordinary income	8,421	7,444	7,332	--	--	(7,444)		--
Extraordinary loss	5,363	4,580	7,903	324	1,246	(3,334)		--
Net income before income taxes	33,270	41,387	46,183	22,769	31,335	(10,051)	76%	45,500
Corporate, local and enterprise taxes	15,507	18,640	20,489	11,212	15,847	(2,793)		--
Income from minority interests	44	74	86	32	47	(26)		--
Net income	17,718	22,672	25,608	11,523	15,440	(7,231)	68%	23,000
Comprehensive income	16,745	15,719	18,693	13,356	18,348	2,629	117%	--
EPS before goodwill amortization (¥/share)	39.24	52.03	61.50	29.40	40.79			58.81

Notes:

- Before amortization of goodwill refers to profit figures prior to the amortization associated with the April 2008 reverse acquisition (share swap with Kirin Pharma.)
- On April 21, 2011, Kyowa Hakko Kirin acquired all outstanding shares of ProStrakan Group plc and as a result ProStrakan Group and its subsidiaries were newly included in the scope of consolidation. However, June 30, 2011 is deemed to be the date the acquisition was completed for accounting purposes and therefore the results of ProStrakan and its subsidiaries were included in the consolidated financial results only for the July-December period of fiscal 2011.
- The FY2012 forecasts are the revised forecasts as announced July 19, 2012.

2. Trends in results by segment

(1) Results by operating segment

Millions of yen, rounded down

	FY 2011 results			FY 2012 results				FY 2012 forecasts
	January 1 to June 30	January 1 to September 30 (A)	January 1 to December 31	January 1 to June 30	January 1 to September 30 (B)	Change on January to September 2011		January to December
						Amount (B-A)	%	
Net sales	186,367	262,358	343,722	166,290	244,691	(17,667)	93%	333,000
Pharmaceuticals	112,534	168,218	229,339	122,833	182,406	14,188	108%	248,000
Bio-Chemicals	40,360	58,973	77,563	40,082	57,488	(1,485)	97%	79,000
Chemicals	33,550	33,550	33,550	--	--	(33,550)	--	--
Other	5,306	7,856	10,659	5,173	7,703	(152)	98%	10,000
Total	191,752	268,598	351,113	168,088	247,597	(21,000)	92%	337,000
Eliminations	(5,384)	(6,239)	(7,390)	(1,798)	(2,906)	3,333	--	(4,000)
Operating income	29,936	38,503	46,614	25,585	37,343	(1,160)	97%	52,000
*Before goodwill amortization	34,576	45,456	55,881	30,212	44,283	(1,173)	97%	61,255
Pharmaceuticals	25,145	33,114	41,314	23,364	34,837	1,722	105%	48,700
Bio-Chemicals	2,519	3,018	2,896	2,040	2,213	(804)	73%	3,000
Chemicals	2,135	2,135	2,135	--	--	(2,135)	--	--
Other	148	255	360	155	259	3	102%	300
Total	29,948	38,524	46,706	25,560	37,311	(1,213)	97%	52,000
Eliminations	(12)	(20)	(92)	24	31	52	--	--

Note:

- All shares of Kyowa Hakko Chemical were divested on March 31, 2011. Consequently, the results of the Chemicals segment in fiscal 2011 are consolidated on the Statements of Income only for the period January-March 2011.

(2) Regional sales

Millions of yen, rounded down

	FY2011 results						FY 2012 results			
	January 1 to June 30	Percentage of consolidated sales	January 1 to September 30	Percentage of consolidated sales	January 1 to December 31	Percentage of consolidated sales	January 1 to June 30	Percentage of consolidated sales	January 1 to September 30	Percentage of consolidated sales
Japan sales	148,987	79.9%	208,194	79.4%	272,568	79.3%	128,898	77.5%	189,990	77.6%
Overseas sales	37,379	20.1%	54,163	20.6%	71,154	20.7%	37,391	22.5%	54,700	22.4%
America	10,456	5.6%	16,083	6.1%	20,071	5.8%	10,097	6.1%	15,080	6.2%
Europe	10,919	5.9%	18,449	7.0%	25,169	7.3%	16,927	10.2%	24,001	9.8%
Asia	15,772	8.5%	19,256	7.3%	25,426	7.4%	10,088	6.1%	15,206	6.2%
Other regions	231	0.1%	374	0.1%	486	0.1%	278	0.2%	412	0.2%
Total consolidated net sales	186,367	100.0%	262,358	100.0%	343,722	100.0%	166,290	100.0%	244,691	100.0%

Note:

Sales are based on the geographic location of the customer and allocated to the appropriate country or region.

3. Trends in non-operating income/expenses

Millions of yen, rounded down

	FY2011 results			FY 2012 results	
	January 1 to June 30	January 1 to September 30	January 1 to December 31	January 1 to June 30	January 1 to September 30
Non-operating income	1,316	1,878	2,233	1,419	1,933
Interest income	193	343	497	285	436
Dividend income	303	334	536	442	477
Foreign exchange gains	112	--	--	--	106
Gain on revaluation of derivatives	--	296	--	16	--
Equity in earnings of affiliates	141	189	199	--	--
Other	565	713	1,000	675	913
Non-operating expenses	1,040	1,858	2,093	3,909	6,694
Interest expenses	77	110	135	81	150
Foreign exchange loss	--	570	154	45	--
Loss on revaluation of derivatives	32	--	142	--	134
Equity in losses of affiliates	--	--	--	2,549	4,643
Loss on disposal of non-current assets	313	453	670	414	631
Other	617	724	990	818	1,135

4. Trends in extraordinary income / loss

Millions of yen, rounded down

	FY 2011 results			FY 2012 results	
	January 1 to June 30	January 1 to September 30	January 1 to December 31	January 1 to June 30	January 1 to September 30
Extraordinary income	8,421	7,444	7,332	--	--
Gain on sales of subsidiaries and affiliates' stocks	8,320	7,339	7,217	--	--
Reversal of allowance for doubtful accounts	100	104	115	--	--
Extraordinary loss	5,363	4,580	7,903	324	1,246
Loss on valuation of investment securities	3,043	2,011	2,374	--	905
Loss on sale of investment securities	--	--	692	324	340
Advisory expenses	1,030	1,062	1,098	--	--
Asset impairment loss	200	273	769	--	--
Loss from natural disaster	302	447	650	--	--
Loss from sale of fixed assets	--	--	635	--	--
Extraordinary depreciation of fixed assets	--	--	477	--	--
Loss on adjustment for changes of accounting standard for asset retirement	447	447	447	--	--
Loss on business liquidation	--	--	419	--	--
Loss on liquidation of affiliates	209	209	209	--	--
Provision for point card certificates for prior periods	128	128	128	--	--

5. Trends in R&D expenses

Billions of yen, rounded down

	FY 2011 results			FY 2012 results		FY 2012 forecasts
	January 1 to June 30	January 1 to September 30	January 1 to December 31	January 1 to June 30	January 1 to September 30	January 1 to December 31
R&D expenses (Consolidated)	22.2	34.0	47.9	22.1	33.6	44.3
R&D to net sales ratio (%)	11.9%	13.0%	14.0%	13.3%	13.8%	13.3%
Pharmaceuticals	20.4	31.5	44.5	20.5	31.3	41.0
(R&D to net sales ratio) (%)	18.2%	18.8%	19.4%	16.8%	17.2%	16.5%
Bio-Chemicals	1.5	2.2	3.2	1.5	2.3	3.3
Chemicals	0.2	0.2	0.2	--	--	--
Other	--	--	--	--	--	--

6. Trends in Capital Expenditure (Tangible fixed assets)

Billions of yen, rounded down

	FY 2011 results			FY 2012 results		FY 2012 forecasts
	January 1 to June 30	January 1 to September 30	January 1 to December 31	January 1 to June 30	January 1 to September 30	January 1 to December 31
Capital expenditure (Consolidated)	5.9	10.4	14.3	7.9	14.7	21.4
Pharmaceuticals	2.8	5.1	6.5	4.0	7.3	10.9
Bio-Chemicals	2.7	4.9	7.4	3.9	7.4	10.4
Chemicals	0.3	0.3	0.3	--	--	--
Other	0.0	0.0	0.0	0.0	0.0	0.0

7. Trends in Depreciation Expenses

Billions of yen, rounded down

	FY 2011 results			FY 2012 results		FY 2012 forecasts
	January 1 to June 30	January 1 to September 30	January 1 to December 31	January 1 to June 30	January 1 to September 30	January 1 to December 31
Depreciation expenses (Consolidated)	10.4	16.2	22.8	9.6	14.5	21.3
Pharmaceuticals	6.8	11.0	15.3	6.6	10.1	14.5
Bio-Chemicals	2.6	4.2	6.4	2.9	4.4	6.7
Chemicals	0.9	0.9	0.9	--	--	--
Other	0.0	0.0	0.0	0.0	0.0	0.0

8. Exchange rates

	FY 2011 results			FY 2012 results		FY 2012 forecasts
	January 1 to June 30	January 1 to September 30	January 1 to December 31	January 1 to June 30	January 1 to September 30	January 1 to December 31
US Dollar (¥/US\$)	82	81	80	80	79	81
Euro (¥/Euro)	115	113	111	103	102	102
GBP (¥/GBP)	132	130	128	126	125	124

II. Consolidated Subsidiaries and Affiliates

(As of September 30, 2012)

Segment	Type	Region	Company name	Percentage owned (direct and indirect)	Principal business
Pharmaceuticals	Consolidated subsidiary	Japan	Kyowa Medex Co., Ltd.	100.0%	Manufacture and sale of diagnostic reagents
			Kyowa Medical Promotion Co., Ltd.	100.0%	Promotion and sales of pharmaceuticals
		The Americas	Kyowa Hakko Kirin America, Inc.	100.0%	Holding company for administration and management of subsidiaries (US)
			BioWa, Inc.	100.0%	Out-licensing of anti-body technology (US)
			Kyowa Hakko Kirin Pharma, Inc.	100.0%	Development of outsourced pharmaceutical products (US)
			Kyowa Hakko Kirin California, Inc.	100.0%	Generate new candidate substances and develop pharmaceuticals (US)
			Hematech, Inc.	100.0%	Technology research for manufacture of therapeutic antibody (US)
			Hematech-GAC Venture, LLC	51.0%	Technology research for manufacture of therapeutic antibody (US)
			ProStrakan Inc.	100.0%	Sales of pharmaceuticals (US)
		Europe	ProStrakan Group plc	100.0%	Supervision and management of special companies (UK)
			Strakan International S.a r.l.	100.0%	Sales, licensing-in and licensing-out of pharmaceuticals (UK)
			Strakan Pharmaceuticals Limited	100.0%	Development of pharmaceuticals (UK)
			ProStrakan Limited	100.0%	Sales of pharmaceuticals (UK)
			ProStrakan Pharma S.A.S	100.0%	Sales of pharmaceuticals (France)
			ProStrakan Farmaceutica SLU	100.0%	Sales of pharmaceuticals (Spain)
			ProStrakan Pharma GmbH	100.0%	Sales of pharmaceuticals (Germany)
			ProStrakan Holdings B.V.	100.0%	Holding company for special companies (Netherlands)
			ProStrakan Pharma B.V.	100.0%	Sales of pharmaceuticals (Netherlands)
			ProStrakan S.r.l.	100.0%	Sales of pharmaceuticals (Italy)
		ProStrakan AB	100.0%	Sales of pharmaceuticals (Sweden)	
	Asia	Kyowa Hakko Kirin China Pharmaceutical Co., Ltd.	100.0%	Manufacture and sale of pharmaceuticals (China)	
		Kyowa Hakko Kirin Korea Co., Ltd.	100.0%	Sales of pharmaceuticals (Korea)	
		Kyowa Hakko Kirin (Taiwan) Co., Ltd.	100.0%	Sales of pharmaceuticals (Taiwan)	
Kyowa Hakko Kirin (Hong Kong) Co., Ltd.		100.0%	Sales of pharmaceuticals (Hong Kong)		
Kyowa Hakko Kirin (Singapore) Pte. Ltd.		100.0%	Sales of pharmaceuticals (Singapore)		
	Affiliate accounted by the equity method	Japan	FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.	50.0%	Development, manufacture and sale of biosimilar products
Bio-Chemicals	Consolidated subsidiary	Japan	Kyowa Hakko Bio Co., Ltd.	100.0%	Manufacture and sale of pharmaceutical and industrial raw materials, and health care products
			Daiichi Fine Chemical Co., Ltd.	100.0%	Manufacture and sale of active pharmaceutical ingredients and pharmaceutical intermediates
			Kyowa Wellness Co., Ltd.	100.0%	Sale of healthcare products
			Kyowa Engineering Co., Ltd.	100.0%	Design and installation of plant facilities and equipment
		The Americas	BioKyowa Inc.	100.0%	Manufacture and sale of amino acids (US)
			Kyowa Hakko U.S.A., Inc.	100.0%	Sale and import/export of fine chemicals including amino acids (US)
			Kyowa Hakko Bio U.S. Holdings, Inc.	100.0%	Holding company for administration and management of US special companies (US)
		Europe	Kyowa Hakko Europe GmbH	100.0%	Sale and import/export of fine chemicals including amino acids (Germany)
			Kyowa Hakko Bio Italia S.r.l.	100.0%	Sale and import/export of fine chemicals including amino acids (Italy)
		Asia	Shanghai Kyowa Amino Acid Co., Ltd.	70.0%	Manufacture and sale of amino acids (China)
Kyowa Hakko (H.K.) Co., Ltd.	100.0%		Sale and import/export of fine chemicals including amino acids (Hong Kong)		
Kyowa Hakko Bio Singapore Pte. Ltd.	100.0%		Sale and import/export of fine chemicals including amino acids (Singapore)		
Other	Consolidated subsidiary	Japan	Chiyoda Kaihatsu Co., Ltd.	100.0%	Transportation, insurance, wholesale sales of food, etc.
	Affiliate accounted by the equity method		Japan Synthetic Alcohol Co., Ltd.	33.3%	Manufacture and sale of industrial use alcohol

Notes: Changes to the scope of consolidation (January 1, 2012 to September 30, 2012)

Newly consolidated: 1 company: ProStrakan AB (*1)

Removed: 1 company: Kyowa Hakko Kirin Italia S.r.l. (*2)

*1 On June 1, 2012, Kyowa Hakko Kirin acquired all outstanding shares of ProStrakan AB which was newly included as a subsidiary in the scope of consolidation.

*2 As of June 1, 2012, Kyowa Hakko Kirin Italia S.r.l. was merged with ProStrakan S.r.l. and eliminated.

*3 As of April 23, 2012, Kirin Kunpeng (China) Bio-Pharmaceutical Co., Ltd. changed its corporate name to Kyowa Hakko Kirin China Pharmaceutical Co., Ltd.

*4 As of June 1, 2012, Jeil-Kirin Pharm. Inc. changed its corporate name to Kyowa Hakko Kirin Korea Co., Ltd.

III. Net sales by division (Items and main products)

1. Kyowa Hakko Kirin

Billions of yen, rounded down

Pharmaceuticals division (non-consolidated)	Fiscal 2011 results			Fiscal 2012 results			FY 2012 forecasts
	January 1 to June 30 results	January 1 to September 30 results (A)	January 1 to December 31 results	January 1 to June 30 results	January 1 to September 30 results (B)	Change on January 1 to September 30, 2011 (B/A)	January 1 to December 31
Pharmaceuticals division total	104.6	152.3	206.0	107.8	159.4	5%	213.9
Indication / Product							
<i>ESA formulation</i> Nesp	25.4	40.4	56.4	26.8	41.0	2%	53.7
<i>ESA formulation</i> Espo	2.7	4.0	5.3	1.9	2.9	-28%	4.0
Nesp and Espo Total	(28.2)	(44.4)	(61.8)	(28.8)	(43.9)	(-1%)	(57.7)
<i>Secondary hyperparathyroidism</i> Regpara	5.3	8.2	11.5	6.2	9.5	16%	13.0
<i>Antiallergenic</i> Allelock	18.1	22.2	29.1	16.1	21.8	-2%	29.1
<i>Antiallergenic</i> Celtect	1.3	1.9	2.5	1.0	1.4	-26%	1.8
<i>Antiallergic eyedrops</i> Patanol	8.6	9.8	11.4	6.9	8.5	-13%	10.1
<i>G-CSF</i> Gran	6.7	10.5	14.8	6.4	9.8	-7%	13.4
<i>Cancer pain</i> Fentos	1.2	2.0	3.1	2.0	3.2	57%	4.5
<i>Anticancer</i> 5-FU	1.5	2.3	3.1	1.4	2.1	-10%	2.7
<i>Anticancer</i> Navelbine	0.8	1.3	1.7	0.6	0.9	-25%	1.2
<i>Cardiovascular</i> Coniel	9.6	14.3	19.7	8.5	12.5	-12%	17.2
<i>Cardiovascular (Hypertension)</i> Coversyl	1.9	2.8	3.9	1.7	2.5	-10%	3.4
<i>Cardiovascular</i> Inovan / Pre Dopa	1.3	2.0	2.8	1.1	1.7	-17%	2.4
<i>Antiepileptic</i> Depakene	5.3	8.1	11.2	5.2	7.8	-4%	10.8
<i>Parkinson's disease</i> Permax	1.1	1.6	2.1	0.8	1.2	-22%	1.7
<i>Gastrointestinal</i> Nauzelin	2.3	3.3	4.8	2.2	3.2	-3%	4.7
<i>Inflammatory bowel disease</i> Asacol	1.1	1.9	2.8	1.8	2.8	45%	3.8
Exports and Technology Licensing Revenue	11.4	17.7	22.3	17.9	26.7	51%	34.7

2. ProStrakan

Millions of GBP, rounded down

Pharmaceuticals division	FY 2011 results			FY 2012 results			FY 2012 forecasts
	January 1 to June 30	January 1 to September 30 (A)	January 1 to December 31	January 1 to June 30	January 1 to September 30, 2012 (B)	Change on January to September 2011 (B/A)	January 1 to December 31
Net sales	48	78	105	61	92	18%	139
Chemotherapy-induced nausea and vomiting drug Sancuso	4	6	9	5	9	46%	16
Management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Abstral	12	20	27	16	24	21%	36
Replacement therapy with testosterone for male hypogonadism Tostran	2	4	5	2	4	8%	4
Prevention and treatment of post-operative nausea and vomiting (PONV). Xomolix	4	6	8	4	6	-7%	9
Relief of pain associated with chronic anal fissures Rectogesic	4	6	9	4	7	4%	9
Osteoporosis drug Adcal-D3	11	17	24	12	19	6%	25
Others	8	16	20	14	21	34%	37
Gross profit	29	50	65	40	64	29%	101
Selling, general and administrative expenses	40	58	75	39	58	-1%	84
Operating income (prior to consolidated adjustment)	(11)	(8)	(9)	1	6	--	17
Consolidated adjustment				(18)	(27)		(34)
Operating income (after consolidated adjustment)				(16)	(20)		(17)

Notes:

1. The results of ProStrakan were consolidated from July 2011.

2. The results of Prostrakan are shown on a local basis (IFRS standards) for fiscal 2011 and on the Kyowa Hakko Kirin standards for fiscal 2012.

The consolidated adjustment amounts are mainly the goodwill and amortization of product sales rights associated with the Prostrakan acquisition.

3. The sales ratio by region is as shown below.

Sales ratio by region (January 1 to September 30, 2012)	UK	Europe (excluding UK)	USA	Other	Total
	33.9%	42.6%	21.6%	1.9%	100.0%

3. Kyowa Hakko Bio

Billions of yen, rounded down

Bio-Chemicals division (non-consolidated)	FY 2011 results			FY 2012 results			FY 2012 forecasts
	January 1 to June 30	January 1 to September 30 (A)	January 1 to December 31	January 1 to June 30	January 1 to September 30 (B)	Change on January to September 2011 (B/A)	January 1 to December 31
Bio-Chemical division total	25.9	38.0	49.6	25.9	38.0	0%	52.1
Pharmaceuticals / Industrial raw materials							
Amino acids	10.1	14.9	19.1	10.2	15.1	1%	20.6
Nucleic acids and vitamins	2.7	4.0	5.2	2.5	3.8	-4%	5.2
Other	3.8	5.4	7.2	3.7	5.4	-1%	6.6
Healthcare products	4.7	7.0	9.3	4.7	7.1	1%	10.1

R&D Pipeline



KYOWA KIRIN

Filed • Approved

As of Oct 18th 2012












Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		Granisetron Patch	5HT3 Serotonin Receptor Antagonist	Chemotherapy induced Nausea and Vomiting	Approved in Taiwan Oct/2012 Filed in Asia	Solasia Pharma (ProStrakan)	Asia: Singapore, Malaysia and Hong Kong
		Cinacalcet Hydrochloride Oral	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Filed in Asia	Licensed from NPS	Asia: Philippine, Malaysia, Thailand and China
Nephrology		KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Pediatric Renal Anemia	Filed in Japan	Kirin-Amgen	
		©KW-6002 Istradefylline Oral	Adenosine A _{2A} Receptor Antagonist	Parkinson's Disease	Filed in USA Filed in Japan	In-House	
Other		AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Idiopathic (Immune) Thrombocytopenic Purpura	Approved in Taiwan Oct/2012	Kirin-Amgen	

Phase II, Phase III

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		KW-2246 Fentanyl Citrate Sublingual Tablet	μ -Opioid Receptor Agonist	Cancer Pain	Phase III in Japan	Licensed from Orexo	
		KRN125 Pegfilgrastim Injection	Long-Acting Granulocyte Colony Stimulating Factor	Chemotherapy induced Febrile Neutropenia	Phase III in Japan	Kirin-Amgen	
		©ARQ 197 Tivantinib Oral	c-Met Inhibitor	Lung Cancer	Phase III in Japan, Korea and Taiwan	Licensed from ArQule	
				Gastric Cancer	Phase II in Japan and Korea		
		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Adult T-cell Leukemia/Lymphoma, Add-on Therapy (for Untreated Patients)	Phase II in Japan	In-House	POTELLIGENT®
				Peripheral T/NK-cell Lymphoma	Phase II in Japan		
				Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma	Phase I / II in USA		
				Peripheral T-cell Lymphoma	Phase II in EU		
		KRN1493 Cinacalcet Hydrochloride Oral	Calcium Receptor Agonist	☆Hypercalcemia with Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism	Phase III in Japan	Licensed from NPS	
		©KW-2478 Injection	HSP90 inhibitor	Multiple Myeloma	Phase I / II in UK/US/PH	In-House	
	KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Myelodysplastic Syndrome related Anemia	Phase II in Japan and Korea	Kirin-Amgen		
Nephrology		KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Renal Anemia (on Dialysis)	Phase II in China	Kirin-Amgen	
		©RTA 402 Bardoxolone Methyl Oral	Antioxidant Inflammation Modulator	CKD in Patients with Type 2 Diabetes	Phase II in Japan	Licensed from Reata	
Immunology /Allergy		©KHK4563 Benralizumab Injection	Anti-IL-5 Receptor Humanized Antibody	Asthma	Phase II in Japan and Korea	In-House	Being Developed by MedImmune as MEDI-563 Worldwide except in Japan and other Asian Countries POTELLIGENT®
		©ASKP 1240 Injection	Anti-CD40 Fully Human Antibody	Organ Transplant Rejection	Phase I in Japan Phase II in USA	In-House	Jointly Developed with Astellas KM mouse
		Z-206 Mesalazine Oral	pH Dependent Controlled Release Tablet	Crohn's Disease	Phase II in Japan	Licensed from Zeria Pharma.	Jointly Developed with Zeria Pharma
Central Nervous System		KW-6485 Topiramate Oral	Antiepileptic Drug	Pediatric Epilepsy	Phase III in Japan	Licensed from Janssen Pharmaceutical K.K.	
		©KHK6188 Oral	Cannabinoid CB2 Receptor Agonist	Neuropathic Pain	Phase II in Japan	In-House	
Other		©KW-3357 Antithrombin Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	Phase III in Japan Phase I in Europe	In-House	

Updated since Jul 17th, 2012 (Area, Stage, Filed, Approved, Launched etc.)

Phase I

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		©KW-2450 Oral	IGF-1 Receptor Signal Inhibitor	Cancer	Phase I / II in USA	In-House	
		©B1W-8962 Injection	Anti-GM2 Humanized Antibody	Cancer	Phase I / IIa in USA	In-House	POTELLIGENT®
		©KRN951 Tivozanib Oral	VEGF Receptor Inhibitor	Cancer	Phase I in Japan	In-House	Filled in US by AVEO as AV-951
		©KHK2866 Injection	Anti-HB-EGF Humanized Antibody	Cancer	Phase I in USA	In-House	POTELLIGENT®
		©LY2523355 Litronisib Injection	M phase Kinesin Eg5 Inhibitor	Cancer	Phase I in Japan	In-House	Being Developed by Eli Lilly as LY2523355 Worldwide except in Japan
		©CEP-37250/K HK2804 Injection	Anti-Tumor Specific Glycoprotein Humanized Antibody	Cancer	Phase I in USA	Cephalon	Jointly Developed with Cephalon POTELLIGENT®
		©KHK2898 Injection	Anti-CD98 Fully Human Antibody	Cancer	Phase I in Singapore	In-House	POTELLIGENT® KM mouse
		©ARQ 197 Tivantinib Oral	c-Met Inhibitor	Hepatocellular Cancer	Phase I in Japan	Licensed from ArQule	
Immunology /Allergy		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Asthma	Phase I in Japan	In-House	POTELLIGENT®
		©KHK4827 Injection	Anti-IL-17 Receptor Fully Human Antibody	Psoriasis	Phase I in Japan	Kirin- Amgen	
Other		©KRN23 Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemic Rickets/Osteomalacia (XLH)	Phase I / II in USA and Canada	In-House	KM mouse




 Updated since Jul 17th, 2012 (Area, Stage, Filed, Approved, Launched etc.)

© New Molecular Entity


Updated since Jul 17th, 2012 (Area, Stage, Filed, Approved, Launched etc.)

Filed • Approved


As of Oct 18th 2012

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		Granisetron Patch	5HT3 Serotonin Receptor Antagonist	Chemotherapy induced Nausea and Vomiting	Approved in Taiwan Oct/2012	Solasia Pharma (ProStrakan)	Asia: Singapore, Malaysia and Hong Kong
Nephrology		KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Pediatric Renal Anemia	Filed in Japan	Kirin- Amgen	
Other		AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Idiopathic (Immune) Thrombocytopenic Purpura	Approved in Taiwan Oct/2012	Kirin- Amgen	



Phase II, Phase III

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Adult T-cell Leukemia/Lymphoma	Phase II in US and EU	In-House	POTELLIGENT®

Phase I

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		©ARQ 197 Tivantinib Oral	c-Met Inhibitor	Hepatocellular Cancer	Phase I in Japan	Licensed from ArQule	

Discontinued

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Reason
Nephrology		KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Renal Anemia (on Dialysis)	Phase III in India	Kirin- Amgen	Reconsidered the product development portfolio based on change in business environment
Oncology		KRN330 Injection	Anti-A33 Fully Human Antibody	Cancer	Phase I / IIa in USA	In-House	Revision for priority of product development portfolio in oncology area